EA200800022A3 - Применение ивабрадина для получения лекарственного средства, предназначенного для лечения эндотелиальной дисфункции - Google Patents

Применение ивабрадина для получения лекарственного средства, предназначенного для лечения эндотелиальной дисфункции

Info

Publication number
EA200800022A3
EA200800022A3 EA200800022A EA200800022A EA200800022A3 EA 200800022 A3 EA200800022 A3 EA 200800022A3 EA 200800022 A EA200800022 A EA 200800022A EA 200800022 A EA200800022 A EA 200800022A EA 200800022 A3 EA200800022 A3 EA 200800022A3
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
dysfunction
ivabradin
endotelial
application
Prior art date
Application number
EA200800022A
Other languages
English (en)
Other versions
EA015398B1 (ru
EA200800022A2 (ru
Inventor
Видаль Бената
Ги Леребу-Пижоньер
Жан-Клод Тардиф
Эрик Торен
Эрик Ром
Original Assignee
Ле Лаборатуар Сервье
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ле Лаборатуар Сервье filed Critical Ле Лаборатуар Сервье
Publication of EA200800022A2 publication Critical patent/EA200800022A2/ru
Publication of EA200800022A3 publication Critical patent/EA200800022A3/ru
Publication of EA015398B1 publication Critical patent/EA015398B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Применение ивабрадина или 3-{3-[{[(7S)-3,4-диметоксибицикло[4.2.0]окта-1,3,5-триен-7-ил]метил}(метил)амино]пропил}-7,8-диметокси-1,3,4,5-тетрагидро-2H-3-бензазепин-2-она, его аддитивных солей с фармацевтически приемлемой кислотой и его гидратов, для получения лекарственного средства, предназначенного для лечения эндотелиальной дисфункции.
EA200800022A 2007-01-11 2008-01-10 Применение ивабрадина для получения лекарственного средства, предназначенного для лечения эндотелиальной дисфункции EA015398B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0700189A FR2911279B1 (fr) 2007-01-11 2007-01-11 Utilisation de l'ivabradine pour l'obtention de medicaments destines au traitement de la dysfonction endotheliale

Publications (3)

Publication Number Publication Date
EA200800022A2 EA200800022A2 (ru) 2008-08-29
EA200800022A3 true EA200800022A3 (ru) 2008-12-30
EA015398B1 EA015398B1 (ru) 2011-08-30

Family

ID=38123876

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800022A EA015398B1 (ru) 2007-01-11 2008-01-10 Применение ивабрадина для получения лекарственного средства, предназначенного для лечения эндотелиальной дисфункции

Country Status (21)

Country Link
US (2) US20080200450A1 (ru)
EP (1) EP1944031A1 (ru)
JP (1) JP2008169213A (ru)
KR (2) KR20080066613A (ru)
CN (1) CN101480398B (ru)
AR (1) AR064832A1 (ru)
AU (1) AU2008200123B2 (ru)
BR (1) BRPI0800001A2 (ru)
CA (1) CA2617363C (ru)
EA (1) EA015398B1 (ru)
FR (1) FR2911279B1 (ru)
GE (1) GEP20115158B (ru)
HK (1) HK1130686A1 (ru)
MA (1) MA29720B1 (ru)
MX (1) MX2008000023A (ru)
MY (1) MY148650A (ru)
NZ (1) NZ564997A (ru)
SG (1) SG144832A1 (ru)
UA (1) UA96574C2 (ru)
WO (1) WO2008099091A2 (ru)
ZA (1) ZA200800358B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2938194B1 (fr) * 2008-11-07 2012-08-31 Servier Lab Utilisation de l'ivabradine comme agent de diagnostic dans la methode d'angiographie coronaire par tomodensitometrie multicoupe
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
CN102908327B (zh) * 2011-08-05 2015-03-11 江苏恒瑞医药股份有限公司 伊伐布雷定或其可药用盐的缓释制剂
GB201312386D0 (en) * 2013-07-10 2013-08-21 Isis Innovation Pharmaceutical compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681862B1 (fr) 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
CN1651087A (zh) * 2000-04-12 2005-08-10 诺瓦提斯公司 有机化合物的联合形式
FR2834896B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'ivabradine
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
AR064832A1 (es) 2009-04-29
NZ564997A (en) 2009-09-25
EA015398B1 (ru) 2011-08-30
AU2008200123A1 (en) 2008-07-31
AU2008200123B2 (en) 2012-08-16
GEP20115158B (en) 2011-02-10
CN101480398B (zh) 2011-07-27
EP1944031A1 (fr) 2008-07-16
WO2008099091A3 (fr) 2008-10-02
KR101359936B1 (ko) 2014-02-10
FR2911279A1 (fr) 2008-07-18
WO2008099091A2 (fr) 2008-08-21
MA29720B1 (fr) 2008-09-01
FR2911279B1 (fr) 2009-03-06
BRPI0800001A2 (pt) 2010-02-23
ZA200800358B (en) 2008-11-26
EA200800022A2 (ru) 2008-08-29
CA2617363A1 (fr) 2008-07-11
UA96574C2 (ru) 2011-11-25
MY148650A (en) 2013-05-15
SG144832A1 (en) 2008-08-28
US20110288072A1 (en) 2011-11-24
JP2008169213A (ja) 2008-07-24
CN101480398A (zh) 2009-07-15
HK1130686A1 (en) 2010-01-08
US20080200450A1 (en) 2008-08-21
CA2617363C (fr) 2012-12-04
KR20080066613A (ko) 2008-07-16
KR20100112540A (ko) 2010-10-19
MX2008000023A (es) 2009-02-23

Similar Documents

Publication Publication Date Title
NZ593437A (en) Use of the association of ivabradine and perindopril in the treatment of heart failure
HK1080362B (zh) 合成伊伐布雷定及其與藥學上可接受的酸的加成鹽的新方法
NO20050888L (no) Ny fremgangsmate for syntesen av 1,3,4,5-tetrahydro-2H-3-benzazepin-2-onforbindelser, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
HRP20110532T1 (hr) Kombinacija inhibitora if struje sinusnog čvora i inhibitora enzima konverzije angiotenzina
HRP20140928T1 (en) Process for the synthesis of the 7,8-dimethoxy-1,3-dihydro-2h-3-benzazepin-2-one, and its application to the synthesis of ivabradine as well as its addition salts with a pharmaceutically acceptable acid
EA200800022A3 (ru) Применение ивабрадина для получения лекарственного средства, предназначенного для лечения эндотелиальной дисфункции
AR058575A1 (es) Asociacion de un inhibidor de la corriente sinusal if y de un inhibidor calcico y las composiciones farmaceuticas que la contienen
GEP20135970B (en) New method of synthesis of ivabradine and pharmaceutically acceptable acid-additive salts thereof
GEP20156235B (en) Process for enzymatic synthesis of (7s)-3,4-dimethoxy-bicyclo-[4.2.0]octa-1,3,5-triene-7- carboxylic acid or esters thereof, and application in synthesis of ivabradine and salts thereof
EA200901369A1 (ru) Применение ивабрадина в качестве диагностического средства в методе коронарной ангиографии путем многослойной компьютерной томографии
CO6290712A2 (es) Asociacion de un inhibidor de corriente sinusual if y de un beta -bloqueante
MD20130016A2 (en) New process for the synthesis of ivabradine and addition salts thereof with pharmaceutically acceptable acids
NZ622915A (en) Process for the synthesis of 7,8-dimethoxy-1,3-dihydro-2h-3-benzazepin-2-one compounds, and application in the synthesis of ivabradine
TH107683B (th) กระบวนการใหม่สำหรับการสังเคราะห์อิวาเบรดีนและเกลือการเติมของสารนี้พร้อม ด้วยกรดที่ยอมรับได้โดยทางเภสัชภัณฑ์
TH137164A (th) การใช้ประโยชน์จากการร่วมกันของสารยับยั้งกระแสไซนัสโหนด If (sinus node If current inhibitor) และสารยับยั้งเอนไซม์ซึ่งเปลี่ยนผันแองจิโอเทนซิน (angiotensin-converting enzyme inhibitor) ในการบำบัดภาวะหัวใจล้มเหลว
TN2009000455A1 (fr) Utilisation de l'ivabradine comme agent de diagnostic dans la methode d'angiographie coronaire par tomodensitometrie multicoupe
TH99437A (th) สารร่วมสมทบชนิดใหม่ของสารยับยั้งกระแสต่อมไซนัส If และ สารยับยั้งเอนไซม์แปลงเปลี่ยน-แอนไจโอเทนซินและองค์ประกอบในทางเภสัชกรรมที่มีสารนั้น
TH137164B (th) การใช้ประโยชน์จากการร่วมกันของสารยับยั้งกระแสไซนัสโหนด If (sinus node If current inhibitor)และสารยับยั้งเอนไซม์ซึ่งเปลี่ยนผันแองจิโอเทนซิน(angiotensin-converting enzyme inhibitor)ในการบำบัดภาวะหัวใจล้มเหลว

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU